Diligence memo · auto-generated · as of July 2, 2026

InnAVasc Medical, Inc.

InnAVasc Medical, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

InnAVasc Medical, Inc. operates in Biotechnology, based in DURHAM.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

InnAVasc Medical, Inc. has raised $4.6M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.1M on 2016-10-21.

Most recent recorded round closed around 2021-11-04.

Valuation (modeled)modeled

Provath models InnAVasc Medical, Inc. at approximately $21M (range $720K–$115M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.33× the median modeled value of Seed Biotechnology companies in 2019–2021 (186 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 17 months.

Last raise 4.7 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 2.4× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 42% of Biotechnology peers (4293 compared).

Modeled value ranks above 29% of those peers.

Closest niche peers: Novo Biosciences, Inc., Entac Medical, Inc., ReGelTec, Inc., Korro Bio, Inc., TamuroBio Inc..

Peoplefiled

18 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.